GW Pharmaceuticals (NASDAQ:GWPH) can forget about convincing Allison Benavides – or Heather Jackson or Liz Minda or many other parents sold on the healing powers of marijuana – to give its cannabis-based drug, Epidiolex, a chance. Even if GW secures regulatory approval to market Epidiolex as a treatment for severe forms of epilepsy, those mothers fully intend to stick with the natural cannabis oils that they currently use to control their children’s seizures instead.
“I would never switch to Epidiolex,” vowed Benavides, a medical social worker and leader of a rapidly growing support group filled with parents who have turned to medical marijuana as the answer to their prayers. “I’m not touching anything that’s working. Epilepsy treatment is very individualized, and I don’t want to rock the boat in any way.”
With her son free of